Search results for "EROI"

showing 10 items of 1497 documents

Steroids in Acute Spinal Cord Injury: All But Gone Within 5 Years.

2019

Background Spinal cord injury (SCI) is a devastating event often leading to poor neurologic outcomes. One of the most widely practiced treatments has been the administration of methylprednisolone. However, today its use has been called into question over concerns of efficacy and safety. The present study evaluated the changes in the practice of steroid administration in acute SCI among members of the National Spinal Society in Poland in comparison with the results of the survey conducted in 2013. Methods The questionnaire, comprising 5 questions, was distributed among 240 spinal surgeons, members of the Polish Society of Spinal Surgery; of these, 97 (40%) responded. The results were compare…

AdultMalemedicine.medical_specialtyTime FactorsAnti-Inflammatory AgentsSpinal cord injuryMethylprednisolone03 medical and health sciences0302 clinical medicineAge groupsSurveys and QuestionnairesMedicineHumansSurveySpinal cord injurySpinal Cord Injuriesbusiness.industryMiddle Agedmedicine.diseaseSpinal surgeryCritical appraisalNeurosurgeonsMethylprednisoloneClinical evidence030220 oncology & carcinogenesisEmergency medicineAcute spinal cord injurySurgeryFemaleSteroidsNeurology (clinical)Polandbusiness030217 neurology & neurosurgerymedicine.drugWorld neurosurgery
researchProduct

Sudden Sensorineural Hearing Loss: Results of intratympanic steroids as salvage treatment

2012

Objective: The aim of the present study was to verify the efficacy and the safety of intratympanic dexamethasone to treat sudden sensorineural hearing loss as salvage therapy. Materials and methods: A prospective study was conducted on patients affected by idiopathic sudden hearing loss who were treated before with some systemic therapy, but without recovery of the hearing The patients able to undergo the study, but who refused salvage treatment were considered as control group. A solution of Dexamethasone 4 mg/ml was then injected through the posterior–inferior quadrant filling completely the middle ear. The follow-up in the following 6 months included an audiogram every month. Results: Th…

AdultMalemedicine.medical_specialtyTympanic MembraneAdolescentNeurosensorial Hearing Loss Steroids treatmentHearing lossHearing Loss SensorineuralSalvage therapyInjections IntralesionalAudiologyRisk AssessmentSystemic therapyDexamethasoneYoung AdultConfidence IntervalsOdds Ratiootorhinolaryngologic diseasesmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedSalvage TherapyAnalysis of VarianceAbsolute threshold of hearingmedicine.diagnostic_testbusiness.industryAudiogramHearing Loss SuddenMiddle AgedTreatment OutcomeSettore MED/31 - OtorinolaringoiatriaOtorhinolaryngologyCase-Control StudiesAnesthesiaAudiometry Pure-ToneFemaleAudiometrymedicine.symptombusinessFollow-Up Studiesmedicine.drugAmerican Journal of Otolaryngology
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct

Intratympanic Dexamethasone/Hyaluronic Acid Mix as an Adjunct to Intravenous Steroid and Vasoactive Treatment in Patients With Severe Idiopathic Sudd…

2011

To evaluate differences in effectiveness (hearing recovery rates) between idiopathic sudden sensorineural hearing loss (ISSNHL) patients treated with intravenous therapy alone and patients treated with a combination of intravenous and intratympanic therapy.Retrospective case review.Tertiary referral hospital center.Ninety-four patients with moderate ISSNHL treated with an intravenous steroid and vasoactive regimen (duration of therapy, 9 ± 2.76 d) and 76 patients with severe ISSNHL treated with a combination regimen of intravenous and intratympanic therapy (duration of therapy, 10 ± 2.71 d) were reviewed. In the latter patients' group, a series of 3 intratympanic injections of a dexamethaso…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss Sensorineuralmedicine.medical_treatmentIntratympanic dexamethasoneDexamethasoneInjectionsSteroidchemistry.chemical_compoundVasoactiveInternal medicineHyaluronic acidotorhinolaryngologic diseasesmedicineHumansIn patientHyaluronic AcidGlucocorticoidsRetrospective Studiesbusiness.industryHearing Loss SuddenSensory SystemsHearing recoveryTreatment OutcomeEndocrinologyOtorhinolaryngologychemistryIntravenous therapyAnesthesiaSudden sensorineural hearing lossInjections IntravenousAudiometry Pure-ToneFemaleSteroidsNeurology (clinical)businessOtology & Neurotology
researchProduct

Severe acute colitis associated with CMV: a prevalence study.

2005

Abstract Background. Cytomegalovirus has been identified as a pathogen that contributes to flares of colitis when detected in colonic specimens of patients with inflammatory bowel disease. Aim. To determine the overall prevalence and the role of cytomegalovirus infection in a consecutive series of patients with acute severe colitis admitted to our department from 2000 to 2003. Methods. Among 42 patients (38 with ulcerative colitis and 4 with Crohn's disease) admitted to our hospital for acute severe colitis, we performed proctoscopy and biopsy together with blood sample for cytomegalovirus determination at the time of admission, regardless of their steroid resistance. Results. In the 42 pat…

AdultMalemedicine.medical_specialtycytomegaloviruGenotypeCongenital cytomegalovirus infectionCytomegalovirusGastroenterologyInflammatory bowel diseaseinflammatory bowel diseaseInternal medicineBiopsymedicinePrevalenceHumansColitisAcute colitissteroid resistanceAgedCrohn's diseaseHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseColitisUlcerative colitisProctoscopyImmunologyCytomegalovirus InfectionsFemalebusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

“Puffy hand syndrome”

2016

Resume La toxicomanie intraveineuse est responsable de nombreuses complications notamment cutanees et infectieuses. Il existe un syndrome rarement observe en rhumatologie se traduisant par des « grosses mains » : le puffy hand syndrome. Nous en rapportons deux cas rencontres en consultation de rhumatologie chez deux patients toxicomanes. Il s’agit d’un œdeme des mains, bilateral, indolore, ne prenant pas le godet, survenant chez un de nos patients pendant l’intoxication par heroine, et chez l’autre 2 ans apres avoir arrete ses injections. Chez nos deux patients les bilans complementaires (biologiques, radiologiques, echographiques) etaient sans particularite, ce qui a permis dans le context…

AdultMalemedicine.medical_specialtymedia_common.quotation_subjectContext (language use)Physical examinationSeverity of Illness IndexSampling Studies030218 nuclear medicine & medical imagingLymphatic System030207 dermatology & venereal diseases03 medical and health sciencesRare Diseases0302 clinical medicineRheumatologyInternal medicineEdemaSeverity of illnessmedicineHumansLymphedema030212 general & internal medicinePhysical Examinationmedia_commonmedicine.diagnostic_testHeroin Dependencebusiness.industryAddictionSyndromeHandmedicine.diseaseDermatologyRheumatologySurgeryLymphedemaEtiologyFemalemedicine.symptombusinessJoint Bone Spine
researchProduct

Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.

1990

Abstract The influence of ciamexone on the activity and course of endocrine orbitopathy was investigated. Fifty-one patients with active orbitopathy classes II-VI were allocated randomly to two groups: over a period of six months, 26 patients received 300 mg/day ciamexone and 25 patients received placebo tablets. In both groups, prednisolone was administered in addition in the first four weeks. Ophthalmological investigations and clinical tests as well as orbit sonography were carried out before as well as one, three and six months after the beginning of therapy. Before and after treatment, computer tomography of the orbit was performed. Symptoms and signs did not show any significant impro…

AdultMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEye diseasePrednisoloneAziridinesPlacebo-controlled studyVisual AcuityPlaceboRandom AllocationEndocrinologyAdjuvants ImmunologicDouble-Blind MethodInternal medicineOrbital DiseasesMedicineHumansExophthalmusIntraocular PressureAgedChemotherapybiologybusiness.industryThyroiditis AutoimmuneEndocrine orbitopathyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseEndocrinologyPrednisoloneCorticosteroidFemalebusinessmedicine.drugActa endocrinologica
researchProduct

Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses o…

2011

Abstract Background Prescription of non-steroidal anti-inflammatory drugs (NSAIDs) should be based on the assessment of both gastrointestinal (GI) and cardiovascular (CV) risk for the individual patient. We aimed to assess the GI/CV risk profile and the pharmacological management of patients with osteoarthritis (OA) in clinical practice. Methods We conducted a cross-sectional, multicentre, observational study of consecutive OA patients that visited 1,760 doctors throughout the Spanish National Health System (NHS) in a single day. The presence of GI risk factors, CV histories, hypertension and current pharmacological treatments was recorded. Results Of the 60,868 patients, 17,105 had a diagn…

AdultMalemedicine.medical_specialtymedicine.drug_classGastrointestinal DiseasesPopulationProton-pump inhibitorlcsh:MedicineOsteoarthritisRisk AssessmentInternal medicineOsteoarthritisMedicineHumansProspective StudiesRisk factorMedical diagnosisMedical prescriptioneducationAgedAged 80 and overMedicine(all)education.field_of_studyCardiovascular Historybusiness.industrylcsh:RAnti-Inflammatory Agents Non-SteroidalGeneral MedicineMiddle Agedmedicine.diseaseDrug UtilizationCross-Sectional StudiesPrescriptionsCardiovascular DiseasesSpainPhysical therapyObservational studyFemaleGuideline AdherencebusinessResearch ArticleBMC Medicine
researchProduct

Ciclosporin and thyroid-stimulating immunoglobulins in endocrine orbitopathy.

1989

The study investigated whether ciclosporin (C) affected the thyroid-stimulating immunoglobulins (TSI) in serum of patients with endocrine orbitopathy (EO). The effect of C was compared with that of prednisone (P). Fifteen patients with EO classes III-V received C (n = 7) or P (n = 8). In addition to the immunosuppressants, five patients with Graves' disease in each group received methimazole (MMI). The stimulation of the cAMP levels in the medium of thyrocyte cultures was determined as a parameter of TSI. The TSI levels were markedly lowered in both groups during and after therapy. C group: before therapy 6.2 pmol/ml +/- 1.63 (100%, mean +/- SEM), during treatment 4.6 pmol/ml +/- 2.28 (74%)…

AdultMalemedicine.medical_specialtymedicine.drug_classGraves' diseasemedicine.medical_treatmentThyroid GlandCyclosporinsPrednisoneInternal medicinemedicineCyclic AMPExophthalmosHumansAgedChemotherapyTriiodothyronineMethimazolebusiness.industryThyroidGeneral MedicineMiddle Agedmedicine.diseaseCiclosporinGraves DiseaseTiterEndocrinologymedicine.anatomical_structureImmunoglobulin GCorticosteroidPrednisoneTriiodothyronineFemalebusinessmedicine.drugImmunoglobulins Thyroid-StimulatingResearch in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie
researchProduct

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

2018

Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…

AdultMalemedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPopulationImmunologyPlaceboAntibodies Monoclonal HumanizedGastroenterologySystemic Lupus ErythematosusSeverity of Illness Index03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineeducationAdverse effectskin and connective tissue diseases030203 arthritis & rheumatologyeducation.field_of_studyLupus erythematosusIntention-to-treat analysisbusiness.industryComplement C3DNAmedicine.diseaseBelimumabRheumatologyIntention to Treat AnalysisTreatment OutcomeAntibodies AntinuclearImmunology and Allergy; Rheumatology; ImmunologyCorticosteroidOriginal ArticleFemalebusinessmedicine.drug
researchProduct